reports
Moody's Ratings downgrades Cambrex's CFR to B3, outlook remains negati...
Moody's Ratings (Moody's) downgraded the ratings of Cambrex Corporation's ("Cambrex") including the Corporate Family Rating (CFR) to B3 from B2 and the Probability of Default Rating (PDR) to B3-PD from B2-PD. Concurrently, Moody's downgraded the rating of the backed senior secured first lien bank fa...
Moody's changes Cambrex's outlook to negative; affirms B2 CFR
Moody's Investors Service ("Moody's") today affirmed Cambrex Corporation's ("Cambrex") B2 corporate family rating (CFR) and B2-PD probability of default rating (PDR). Concurrently, Moody's affirmed the B2 rating of the backed senior secured first lien bank facility. The outlook was changed to negati...
Cambrex Completes Biopharmaceutical Expansion at its Durham, NC Facili...
Cambrex Completes Biopharmaceutical Expansion at its Durham, NC Facility EAST RUTHERFORD, N.J., April 07, 2020 (GLOBE NEWSWIRE) -- Cambrex, the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced it has completed an expansion of its biopharmaceutical analysis capabilities at the Durham, North Carolina site. Biopharmaceutical analysis services were initially launched at Durham in 2018 and have since been expanded through the purchase and implementation of various method development, validation, rele...
Cambrex Appoints Troy Player as President, Early Stage Development & T...
Cambrex Appoints Troy Player as President, Early Stage Development & Testing Business Unit EAST RUTHERFORD, N.J., March 31, 2020 (GLOBE NEWSWIRE) -- Cambrex, the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that Troy Player has been appointed as President, Early Stage Development and Testing (ESDT). In his new role, he has responsibility for operations at the Agawam, Massachusetts; Durham, North Carolina; Edinburgh, UK; High Point, North Carolina and Longmont, Colorado facilities. With more...
Cambrex Announces Management Changes and Board Appointments
Cambrex Announces Management Changes and Board Appointments EAST RUTHERFORD, N.J., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Cambrex Corporation, the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced changes to its management team and Board of Directors to accelerate growth and further operational excellence, building upon its trusted reputation for the highest quality pharmaceutical development and manufacturing capabilities. The following appointments and new positions are effective immediately. ...
Cambrex Announces Completion of Acquisition by the Permira Funds
Cambrex Announces Completion of Acquisition by the Permira Funds EAST RUTHERFORD, N.J., Dec. 04, 2019 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced the completion of its previously announced sale to an affiliate of the Permira funds. The Permira funds’ investment will support the ongoing growth of Cambrex’s integrated services offering by enhancing the company’s ability to service its global customer base, and broadening its capabiliti...
Cambrex Wins Third API Development Award at CPhI Worldwide
Cambrex Wins Third API Development Award at CPhI Worldwide EAST RUTHERFORD, N.J., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, has won the ‘Excellence in Pharma: API Development’ category at the annual CPhI Pharma Awards, which took place at a Gala Dinner at CPhI Worldwide in Frankfurt on November 5th. This marks the third time that Cambrex has won the category in the past 4 years, having previously won in 2016 and 2017. The Company was ...
Moody's assigns B3 CFR rating to Cambrex Corporation; outlook stable
Rating Action: Moody's assigns B3 CFR rating to Cambrex Corporation; outlook stable. Global Credit Research- 04 Nov 2019. New York, November 04, 2019-- Moody's Investors Service assigned ratings to Cambrex Corporation, including a B3 Corporate Family Rating and B3-PD Probability of Default Rating.
Cambrex Releases Selected Preliminary Third Quarter 2019 Financial Res...
Cambrex Releases Selected Preliminary Third Quarter 2019 Financial Results EAST RUTHERFORD, N.J., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that in connection with the debt portion of the financing for the pending acquisition by an affiliate of the Permira Funds, they are making the following third quarter 2019 preliminary unaudited financial information available to prospective lenders. CAMBREX CORPORATION For the Th...
Cambrex Corporation Announces Expiration of “Go Shop†Period Under...
Cambrex Corporation Announces Expiration of “Go Shop” Period Under Merger Agreement EAST RUTHERFORD, N.J., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM) (the “Company” or “Cambrex”) today announced the expiration, as of 12:01 a.m., Eastern Time, on September 22, 2019, of the 45-day “go shop” period under the previously announced Agreement and Plan of Merger, dated as of August 7, 2019 (the “Merger Agreement”), which provides for the Company to be acquired by an affiliate of the Permira funds in an all-cash transaction for $60.00 per share. At the direction of the ad h...
Cambrex Cancels Second Quarter Earnings Conference Call and Will Not U...
Cambrex Cancels Second Quarter Earnings Conference Call and Will Not Update Financial Guidance EAST RUTHERFORD, N.J., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that it will not hold a second quarter 2019 earnings conference call and will not update previously provided financial guidance given the pending acquisition by an affiliate of the Permira funds. About CambrexCambrex is the leading small molecule company that...
Cambrex to be Acquired by the Permira Funds for $60.00 per Share in Ca...
Cambrex to be Acquired by the Permira Funds for $60.00 per Share in Cash EAST RUTHERFORD, N.J., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, announced today that it has signed a definitive agreement to be acquired by an affiliate of the Permira funds in a transaction valued at approximately $2.4 billion, including Cambrex’s net debt. Under the terms of the merger agreement, Cambrex shareholders will receive $60.00 in cash for each share...
Cambrex to Announce Second Quarter 2019 Financial Results on August 9,...
Cambrex to Announce Second Quarter 2019 Financial Results on August 9, 2019 EAST RUTHERFORD, N.J., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that second quarter 2019 financial results will be released on Friday, August 9, 2019 before the market opens. The Company will host a conference call to discuss the financial results. Second Quarter 2019 Earnings Conference Call When:Friday, August 9, 2019 at 8:30 a.m. Eastern...
Cambrex to Double Size of Edinburgh Solid Form Screening Facility
Cambrex to Double Size of Edinburgh Solid Form Screening Facility EAST RUTHERFORD, N.J., July 30, 2019 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that it is expanding its solid form screening and crystallization process development facility in Edinburgh, Scotland, doubling the current footprint to 15,000 sq. ft. The site currently has 50 employees and the expansion will add additional laboratory space to enable the recruitment of up ...
Cambrex Strengthens Leadership Team to Support Integrated Small Molecu...
Cambrex Strengthens Leadership Team to Support Integrated Small Molecule End-to-End Service Offering EAST RUTHERFORD, N.J., June 26, 2019 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced three senior appointments to further support the company’s strategy to create the Contract Development and Manufacturing Organization (CDMO) of choice for small molecules within the pharmaceutical industry. Bruno Biscaro has been appointed President, Drug...
Cambrex Appoints Dottie Donnelly-Brienza as Senior Vice President and ...
Cambrex Appoints Dottie Donnelly-Brienza as Senior Vice President and Chief Human Resources Officer EAST RUTHERFORD, N.J., June 25, 2019 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that Dottie Donnelly-Brienza has been appointed Senior Vice President and Chief Human Resources Officer. In this new role, she will have global responsibility for the company’s human resources function, and will join the company’s executive management team....
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.